Hollings Home  
 
Yubin Kang, MD
Assistant Professor of Medicine
Hematology/Oncology
College of Medicine
MUSC

Email: kangy@musc.edu
 
       Print This Page
       
 
 


 

Yubin Kang, MD

Return to Search Page  

Research Interest:

I am a physician scientist and both my research and clinical interests are focused on hematopoietic stem cell biology and transplantation. When I was a fellow in the laboratory of Dr. Nelson Chao at Duke University, I found that post-transplant administration of plerixafor improved animal survival and enhanced donor cell engraftment in murine transplant models. I also performed extensive mechanistic studies. My laboratory has now moved forward and translated my research findings into a clinical trial to improve donor cell recovery in myeloablative allogeneic HCT patients. The clinical trial thus far has demonstrated feasibility and safety of repeated doses of plerixafor after HCT, and the preliminary efficacy analysis is encouraging. These studies have important implications in our understanding the roles of CXCR4/SDF-1 interaction in hematopoiesis and in improving transplant outcomes. I have extensive training and experience in both basic science and clinical practice that allow me to fully understand the importance and logistics of translational research.

Selected Publications:

1.Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. .124(12):1915-25, 2014. PMID: 25122609 PMCID: PMC4168346
View in: PubMed

2.Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion. .54(12):3131-7, 2014. PMID: 24947954
View in: PubMed

3.An N, Kang Y. Thioredoxin and hematologic malignancies. Adv Cancer Res. .122:245-79, 2014. PMID: 24974184
View in: PubMed

4.Kellner J, Liu B, Kang Y, Li Z. Fact or fiction--identifying the elusive multiple myeloma stem cell. J Hematol Oncol. .6:91, 2013. PMID: 24314019 PMCID: PMC4029203
View in: PubMed

5.Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP, Edwards KH, Kang Y, Gertz MA, Stuart RK, Kumar S. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. Biol Blood Marrow Transplant. .20(2):222-8, 2013. PMID: 24211319
View in: PubMed

6.An N, Janech MG, Bland AM, Lazarchick J, Arthur JM, Kang Y. Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution. Exp Hematol. .41(11):944-56, 2013. PMID: 23994289 PMCID: PMC3955273
View in: PubMed

7.An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS, Kang Y. Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells. .31(6):1202-12, 2013. PMID: 23495171 PMCID: PMC3664117
View in: PubMed

8.An N, Kang Y. Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation model. J Vis Exp. .(73):e50193, 2013. PMID: 23525072 PMCID: PMC3622101
View in: PubMed

9.Coker WJ, Jeter A, Schade H, Kang Y. Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. Biomark Res. .1(1):8, 2013. PMID: 24252328 PMCID: PMC4177611
View in: PubMed

10.An N, Kraft AS, Kang Y. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol. .6:12, 2013. PMID: 23360755 PMCID: PMC3610283
View in: PubMed

11.Zhou D, Deoliveira D, Kang Y, Choi SS, Li Z, Chao NJ, Chen BJ. Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation. Int J Radiat Oncol Biol Phys. .85(4):1141-8, 2012. PMID: 23021438 PMCID: PMC3562560
View in: PubMed

12.Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. .89(5):432-4, 2012. PMID: 22971164
View in: PubMed

13.Jeter A, Kang Y. Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy. Exp Hematol Oncol. .1(1):20, 2012. PMID: 23211009 PMCID: PMC3514086
View in: PubMed

14.Butler C, Wolff DJ, Kang Y, Stuart RK, Costa LJ. Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma. .53(12):2444-8, 2012. PMID: 22574971
View in: PubMed

15.Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. .47(11):1403-8, 2012. PMID: 22484324
View in: PubMed

16.Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. .52(11):2375-81, 2012. PMID: 22404694
View in: PubMed

17.Kang Y, Chen BJ, Deoliveira D, Mito J, Chao NJ. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One. .5(6):e11316, 2010. PMID: 20596257 PMCID: PMC2893128
View in: PubMed

18.Kang Y, Chao NJ, Aversa F. Unmanipulated or CD34 selected haplotype mismatched transplants. Curr Opin Hematol. .15(6):561-7, 2008. PMID: 18832926
View in: PubMed

19.Kang Y, Moressi CJ, Scheetz TE, Xie L, Tran DT, Casavant TL, Ak P, Benham CJ, Davidson BL, McCray PB. Integration site choice of a feline immunodeficiency virus vector. J Virol. .80(17):8820-3, 2006. PMID: 16912328 PMCID: PMC1563849
View in: PubMed

20.Kang Y, Xie L, Tran DT, Stein CS, Hickey M, Davidson BL, McCray PB. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood. .106(5):1552-8, 2005. PMID: 15886327 PMCID: PMC1895217
View in: PubMed

21.Song L, Wang J, Wang R, Yu M, Sun Y, Han G, Li Y, Qian J, Scott DW, Kang Y, Soukhareva N, Shen B. Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta? Gene Ther. .11(20):1487-96, 2004. PMID: 15343360
View in: PubMed

22.Starner TD, Barker CK, Jia HP, Kang Y, McCray PB. CCL20 is an inducible product of human airway epithelia with innate immune properties. Am J Respir Cell Mol Biol. .29(5):627-33, 2003. PMID: 12748059
View in: PubMed

23.Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, Sharkey CM, Sanders DA, McCray PB, Davidson BL. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol. .76(18):9378-88, 2002. PMID: 12186920 PMCID: PMC136422
View in: PubMed

24.Melo ME, Qian J, El-Amine M, Agarwal RK, Soukhareva N, Kang Y, Scott DW. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol. .168(9):4788-95, 2002. PMID: 11971030
View in: PubMed

25.Stein CS, Kang Y, Sauter SL, Townsend K, Staber P, Derksen TA, Martins I, Qian J, Davidson BL, McCray PB. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther. .3(6):850-6, 2001. PMID: 11407898
View in: PubMed

26.El-Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol. .165(10):5631-6, 2000. PMID: 11067919
View in: PubMed

27.Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest. .106(2):245-52, 2000. PMID: 10903340 PMCID: PMC517488
View in: PubMed

28.Kang Y, Melo M, Deng E, Tisch R, El-Amine M, Scott DW. Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci U S A. .96(15):8609-14, 1999. PMID: 10411923 PMCID: PMC17564
View in: PubMed

29.Kang Y, Melo EF, Scott DW. An ongoing immune response to HIV envelope gp120 in human CD4-transgenic mice contributes to T cell decline upon intravenous administration of gp120. Eur J Immunol. .28(8):2253-64, 1998. PMID: 9710203
View in: PubMed

30.Thornalley PJ, Ladan MJ, Ridgway SJ, Kang Y. Antitumor activity of S-(p-bromobenzyl)glutathione diesters in vitro: a structure-activity study. J Med Chem. .39(17):3409-11, 1996. PMID: 8765525
View in: PubMed

31.Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ, Double J. Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol. .51(10):1365-72, 1996. PMID: 8787553
View in: PubMed

32.Kang Y, Edwards LG, Thornalley PJ. Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leuk Res. .20(5):397-405, 1996. PMID: 8683979
View in: PubMed